ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- RNA Sequencing Reveals Inflammatory and Metabolic Changes in the Lung and Brain After Carbon Black and Naphthalene Whole Body Inhalation Exposure in a Rodent Model of Military Burn Pit Exposures.International journal of molecular sciences · 2025Article
- The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma.The Journal of pathology · 2025Article
- Chromatin Interaction and Histone Mark Signatures Associated With TBXT Expression in Metastatic Lung Cancer.Genes, chromosomes & cancer · 2025Article
- Effect of β-catenin on hypoxia induced epithelial mesenchymal transition in HK-2 cells by regulating Brachyury.Biochemistry and biophysics reports · 2025Article
- Context-dependent T-BOX transcription factor family: from biology to targeted therapy.Cell communication and signaling : CCS · 2024Review
- TBXT dose sensitivity and the decoupling of nascent mesoderm specification from EMT progression in 2D human gastruloids.Development (Cambridge, England) · 2024Article
- Activation of Wnt Pathway Suppresses Growth of MUG-Chor1 Chordoma Cell Line.Cell biochemistry and biophysics · 2023Article
- TBXT dose sensitivity and the decoupling of nascent mesoderm specification from EMT progression in 2D human gastruloids.bioRxiv : the preprint server for biology · 2023Article
- Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8.Cancers · 2023Article
- Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.Cancer immunology, immunotherapy : CII · 2023Article
- Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.Molecular carcinogenesis · 2023Article
- Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.Scientific reports · 2023Article
- T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.Oncogene · 2022Article
- Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.International journal of molecular sciences · 2022Review
- Emerging target discovery and drug repurposing opportunities in chordoma.Frontiers in oncology · 2022Review
- Knockdown of Brachyury Suppresses Breast Cancer Cell Proliferation and Migration via Targeting E2F3.Journal of oncology · 2022Article
- Brachyury promotes proliferation and migration of hepatocellular carcinoma via facilitating the transcription of NCAPG2.American journal of cancer research · 2022Article
- Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.Journal for immunotherapy of cancer · 2021Article
- miR-219-5p targets TBXT and inhibits breast cancer cell EMT and cell migration and invasion.Bioscience reports · 2021Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 2 countries.
Funding
Abstract
purposeThe epithelial-mesenchymal transition (EMT) is emerging as a critical factor for the progression and metastasis of carcinomas, as well as drug resistance. The T-box transcription factor Brachyury has been recently characterized as a driver of EMT in human carcinoma cells. The purpose of this study was to characterize Brachyury as a potential target for lung cancer therapy. EXPERIMENTAL
designThe expression of Brachyury was evaluated by PCR and by immunohistochemistry in human lung tumors and adult normal tissues. Brachyury gene copy number and promoter methylation status were analyzed in tumor tissues with various levels of Brachyury expression. Lung carcinoma cells' susceptibility to T-cell lysis and EGF receptor (EGFR) kinase inhibition were also evaluated relative to the levels of Brachyury.
resultsOur results showed Brachyury protein expression in 41% of primary lung carcinomas, including 48% of adenocarcinomas and 25% of squamous cell carcinomas. With the exception of normal testis and some thyroid tissues, the majority of normal tissues evaluated in this study were negative for the expression of Brachyury protein. Brachyury-specific T cells could lyse Brachyury-positive tumors and the level of Brachyury corresponded to resistance of tumor cells to EGFR kinase inhibition.
conclusionWe hypothesize that the elimination of Brachyury-positive tumor cells may be able to prevent and/or diminish tumor dissemination and the establishment of metastases. The ability of Brachyury-specific T-cell lines to lyse Brachyury-positive tumor cells, in vitro, supports the development of Brachyury-based immunotherapeutic approaches for the treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.